Tag: big pharma

Horseshoe crab blood is key to making a COVID-19 vaccine—but the ecosystem may suffer.

Each spring, guided by the full moon, hundreds of thousands of horseshoe crabs clamber onto beaches across the U.S. mid-Atlantic to lay their eggs. For hungry birds, it’s a cornucopia. For drug companies, it’s a crucial resource for making human medicines safe.

That’s because these animals’ milky-blue blood provides the only known natural source of limulus amebocyte lysate, a substance that detects a contaminant called endotoxin. If even tiny amounts of endotoxin—a type of bacterial toxin—make their way into vaccines, injectable drugs, or other sterile pharmaceuticals such as artificial knees and hips, the results can be deadly.

“All pharmaceutical companies around the world rely on these crabs. When you think about it, your mind is boggled by the reliance that we have on this primitive creature,” says Barbara Brummer, state director for The Nature Conservancy in New Jersey.

Every year, pharmaceutical companies round up half a million Atlantic horseshoe crabs, bleed them, and return them to the ocean— after which many will die. This practice, combined with overharvesting of the crabs for fishing bait, has caused a decline in the species in the region in the past few decades.

Keep reading

DOD Awards $104 Million for Procurement of Syringes in Support of U.S. COVID-19 Vaccination Campaign

On August 4, the Department of Defense’s (DOD) Joint Acquisition Task Force (JATF), in support of the Department of Health and Human Services’ (HHS) Strategic National Stockpile (SNS), awarded $104 million in contracts to procure syringes and safety needles, enabling the nationwide administration of a U.S. Food and Drug Administration (FDA)-approved COVID-19 vaccine, once one is available. The syringes and safety needles are critical to the nation’s COVID-19 vaccination strategy, providing a total of 500 million safety syringes over a 12-month period, with more than 134 million of the total number delivered by the end of 2020.

The syringes and safety needles will be placed into the SNS so they will be readily available to quickly and efficiently vaccinate the U.S. population once a safe and efficacious COVID-19 vaccine is developed. This procurement is the latest in a series of recent contracts highlighting a collaborative “whole-of-government” approach in response to the COVID-19 threat.

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) partnered with HHS and the Army Contracting Command – Aberdeen Proving Ground (ACC-APG), to select and award contracts to six companies: Duopross Meditech Corporation ($48 million), Cardinal Health Inc. ($15 million), Gold Coast Medical Supply, LP ($14 million), HTL STREFA Inc. ($12 million), Quality Impact, Inc. ($9 million), and Medline Industries, Inc. ($6 million). The companies represent a mix of large and small medical product manufacturers and distributors.

Keep reading